Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 2/20 | 0.41 | |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14607214 | 0.86 | PDF (0.41) | PDFCCKBRNPY5RKLK7CTSL | |
| SCHEMBL14573079 | 0.83 | PDF (0.48) | PDFCCKBRNPY5RKLK7CTSL | |
| SCHEMBL5657915 | 0.82 | PDF (0.58) | PDFEPHX2 | |
| SCHEMBL3324815 | 0.77 | CTSD (0.42) | CTSLCTSBCTSKMETAP2METAP1 | |
| SCHEMBL3324823 | 0.77 | CTSD (0.42) | CTSLCTSBCTSKMETAP2METAP1 | |
| SCHEMBL3319798 | 0.76 | LTA4H (0.45) | CTSKMETAP2METAP1 | |
| SCHEMBL3319795 | 0.76 | LTA4H (0.45) | CTSKMETAP2METAP1 | |
| SCHEMBL5660726 | 0.72 | — | — | |
| SCHEMBL3320499 | 0.72 | MMP1 (0.41) | — | |
| SCHEMBL3320496 | 0.72 | MMP1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192953-B2 | Antibacterial agents | VERNALIS (OXFORD) LIMITED (GB) | 2007-03-20 | — | — | US | disclosed |
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | VERNALIS (OXFORD) LIMITED (GB) | 2006-06-15 | — | — | US | disclosed |
| EP-1567504-A1 | ANTIBACTERIAL AGENTS | Vernalis (Oxford) Ltd (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050638-A1 | ANTIBACTERIAL AGENTS | VERNALIS (OXFORD) LTD. (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128811-A1 | Hydroxamic acid- and N-formyl hydroxylamine hydrazide derivatives; veterinary medicine | HRH2, HCAR3, HCAR2 | PDF 158/4885CCKBR 1046/4885NPY5R 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.